New combo therapy aims to control returning lung cancer in targeted patients
NCT ID NCT07279935
First seen Jan 04, 2026 · Last updated Jun 18, 2026 · Updated 21 times
Summary
This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. About 100 participants in China will receive this combination and be monitored for how long the cancer stays stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBeijing, 100021, China
-
Research Site
RECRUITINGBeijing, 100044, China
-
Research Site
NOT_YET_RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
NOT_YET_RECRUITINGChengdu, 610041, China
-
Research Site
NOT_YET_RECRUITINGChongqing, 400016, China
-
Research Site
RECRUITINGFuzhou, 350001, China
-
Research Site
RECRUITINGFuzhou, 350005, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510080, China
-
Research Site
WITHDRAWNGuangzhou, 510100, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510289, China
-
Research Site
RECRUITINGHangzhou, 310020, China
-
Research Site
NOT_YET_RECRUITINGHefei, 230022, China
-
Research Site
WITHDRAWNHefei, 230031, China
-
Research Site
WITHDRAWNJinan, 250014, China
-
Research Site
RECRUITINGJinan, 250014, China
-
Research Site
WITHDRAWNKunming, 650118, China
-
Research Site
RECRUITINGNanchang, 330006, China
-
Research Site
NOT_YET_RECRUITINGNanchang, 330006, China
-
Research Site
WITHDRAWNNanjing, 2100008, China
-
Research Site
RECRUITINGNanjing, 210009, China
-
Research Site
RECRUITINGNingbo, 315010, China
-
Research Site
NOT_YET_RECRUITINGShanghai, 200030, China
-
Research Site
WITHDRAWNShanghai, 200120, China
-
Research Site
WITHDRAWNShanghai, 200433, China
-
Research Site
NOT_YET_RECRUITINGShenyang, 110004, China
-
Research Site
RECRUITINGShenyang, 110042, China
-
Research Site
RECRUITINGTianjin, 300060, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430022, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430030, China
-
Research Site
RECRUITINGXi'an, 710004, China
-
Research Site
WITHDRAWNXi'an, 710061, China
-
Research Site
RECRUITINGZhengzhou, 450008, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.